ARTICLE | Company News
1ST Bio partners with Neuraly for PD
December 1, 2017 10:04 PM UTC
1ST Bio Therapeutics Inc. (Seongnam, South Korea) partnered with Neuraly Inc. to co-develop brain penetrant inhibitors of ABL proto-oncogene 1 non-receptor tyrosine kinase (ABL; ABL1) to treat Parkinson's disease. Neuraly spun out of Johns Hopkins University.
1ST Biotherapeutics will be responsible for preclinical development, and Neuraly will test the candidates in various preclinical models of PD. The companies said their goal is to submit an IND to FDA next year. ...
BCIQ Company Profiles
BCIQ Target Profiles
ABL proto-oncogene 1 non-receptor tyrosine kinase (ABL) (ABL1)